Intuitive Surgical, Inc.

(NASDAQ Global Select)
Back to all articles
Bullish +55

Intuitive Surgical Reports Tuesday. It Has Already Beaten Four Times in ...

Earnings report Market commentary Product launch AI-generated analysis

πŸ“ˆ Intuitive Surgical is set to report Q3 earnings with consensus estimates of $2.61-$2.65 EPS and $2.88 billion revenue.

πŸš€ Combined da Vinci and Ion procedures grew 17% in Q1 and 16% in Q2, driving first-half revenues up 21% to $5.66 billion.

πŸ”§ Da Vinci 5 adoption accelerated in Q2 with 246 systems placed, contributing to a global installed base exceeding 11,700 units.

🌍 International procedure growth reached 19% in Q1, with Q2 expansion outside the U.S. driven primarily by general surgery.

πŸ’° The Ion lung biopsy platform has expanded into 12 countries outside the United States, diversifying revenue streams.

⚠️ ISRG trades at a premium valuation of roughly 49x trailing earnings, leaving limited margin for any earnings miss.

πŸ‡¨πŸ‡³ Competitive pressure from domestic robotic surgery companies in China poses a genuine risk to market dominance.

πŸ“‰ High macroeconomic vulnerability exists due to the Philadelphia Semiconductor Index's recent worst eight-day streak since 2008.

🎯 Key metrics for Q3 include maintaining 16% procedure volume growth and holding gross margin guidance at 68%-69%.

🏦 UBS maintains a Buy rating with a $500 target price, while the consensus average across 22 analysts is near $499.

Bullish Signals
  • Intuitive Surgical has beaten earnings estimates for four consecutive quarters, demonstrating consistent execution and market demand.
  • Combined da Vinci and Ion procedure volumes grew 17% in Q1 and 16% in Q2, validating the core business engine.
  • First-half revenues rose approximately 21% to $5.66 billion, reflecting strong top-line growth driven by system placements.
  • The Da Vinci 5 system saw significant adoption with 246 units placed in Q2, up from 180 a year earlier.
  • International da Vinci procedure growth ran at 19% in Q1, indicating successful global expansion strategies.
  • The Ion platform has successfully expanded to 12 countries outside the United States, diversifying geographic revenue.
  • Management maintained full-year 2026 non-GAAP gross margin guidance at 68% to 69%, confirming operating leverage.
  • Analyst consensus targets near $499 imply roughly 17% upside from current trading levels of $426.
Risk Factors
  • The stock trades at a deep discount to its 52-week high, sitting 29% below $603.88 despite recent gains.
  • A valuation premium of roughly 49x trailing earnings leaves limited margin for disappointment in the next report.
  • Competitive pressure from domestic robotic surgery companies is gaining share in China, a previously unchallenged market.
  • Tariffs are cited as an ongoing factor impacting margins, adding uncertainty to financial performance.
  • The Philadelphia Semiconductor Index's recent worst eight-day streak since 2008 adds macroeconomic vulnerability to the stock.
Full Analysis
Intuitive Surgical (ISRG) is preparing to release its Q3 earnings, with the stock trading at $426, significantly below its 52-week high despite recent institutional buying and a 12% gain over the past month. Analysts expect EPS between $2.61 and $2.65 on revenue of approximately $2.88 billion, representing year-over-year growth of roughly 9% and 15% respectively. The company has successfully beaten these consensus estimates for four consecutive quarters, establishing a strong track record of performance. Procedure volume remains the primary engine driving Intuitive Surgical's growth, with combined da Vinci and Ion procedures increasing by 17% in Q1 and 16% in Q2. For the first half of the year, revenues climbed approximately 21% to $5.66 billion, fueled largely by the adoption of the latest Da Vinci 5 system, which accounted for 246 of the 468 systems placed in Q2. The global installed base now exceeds 11,700 da Vinci systems, indicating robust market penetration. International expansion continues to be a key growth vector, particularly for the Ion lung biopsy platform and general surgery procedures outside the United States. While procedure volume growth has outpaced the 13.5% to 15.5% guidance provided for 2026, the stock's high valuation multiple of roughly 49x trailing earnings leaves little room for disappointment. Investors will be closely watching whether Q3 can maintain the 16% procedure growth pace seen in Q2. Competitive pressures in China and macroeconomic factors like tariffs present ongoing risks to Intuitive Surgical's margins and market share. Management has maintained full-year 2026 non-GAAP gross margin guidance between 68% and 69%, citing tariffs as a persistent factor. With analyst consensus targets near $499, the stock implies roughly 17% upside, but the high valuation requires sustained business momentum to justify the premium.